Intrexon (NASDAQ:XON) Lowered to Sell at BidaskClub

Share on StockTwits

Intrexon (NASDAQ:XON) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Tuesday, BidAskClub reports.

Other equities research analysts also recently issued research reports about the stock. Bank of America cut their target price on shares of Intrexon from $7.00 to $6.00 and set an “underperform” rating for the company in a research report on Friday, August 9th. Northland Securities reissued a “hold” rating and set a $10.00 price objective on shares of Intrexon in a research report on Monday, August 12th. Finally, ValuEngine upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $17.00.

XON traded up $0.04 on Tuesday, hitting $5.20. The company had a trading volume of 54,368 shares, compared to its average volume of 968,146. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.55 and a quick ratio of 3.20. Intrexon has a 52-week low of $3.95 and a 52-week high of $14.10. The business has a fifty day simple moving average of $5.87. The firm has a market cap of $836.28 million, a price-to-earnings ratio of -3.80 and a beta of 2.35.

Intrexon (NASDAQ:XON) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.05. Intrexon had a negative net margin of 368.47% and a negative return on equity of 31.89%. The business had revenue of $35.99 million during the quarter, compared to analyst estimates of $29.62 million. During the same period last year, the business posted ($0.51) earnings per share. Intrexon’s quarterly revenue was down 20.6% compared to the same quarter last year. On average, analysts anticipate that Intrexon will post -0.9 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. PFG Advisors increased its holdings in shares of Intrexon by 21.7% in the 2nd quarter. PFG Advisors now owns 12,350 shares of the biotechnology company’s stock worth $94,000 after buying an additional 2,200 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in Intrexon by 4.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 58,956 shares of the biotechnology company’s stock valued at $452,000 after purchasing an additional 2,600 shares during the last quarter. LPL Financial LLC grew its holdings in Intrexon by 15.8% during the 2nd quarter. LPL Financial LLC now owns 19,494 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 2,659 shares during the last quarter. First Republic Investment Management Inc. grew its holdings in Intrexon by 13.9% during the 2nd quarter. First Republic Investment Management Inc. now owns 41,000 shares of the biotechnology company’s stock valued at $314,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Intrexon by 1.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 417,274 shares of the biotechnology company’s stock valued at $3,197,000 after purchasing an additional 5,612 shares during the last quarter. Institutional investors and hedge funds own 75.73% of the company’s stock.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

See Also: What Factors Can Affect Return on Equity?

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Deutsche Bank Reiterates “CHF 350” Price Target for Zurich Insurance Group
Deutsche Bank Reiterates “CHF 350” Price Target for Zurich Insurance Group
Desjardins Analysts Increase Earnings Estimates for Boardwalk Real Estate Investment Trust
Desjardins Analysts Increase Earnings Estimates for Boardwalk Real Estate Investment Trust
Raymond James Analysts Give Crescent Point Energy  a C$5.50 Price Target
Raymond James Analysts Give Crescent Point Energy a C$5.50 Price Target
CAE  Receives “Market Perform” Rating from Raymond James
CAE Receives “Market Perform” Rating from Raymond James
58.com  Scheduled to Post Quarterly Earnings on Tuesday
58.com Scheduled to Post Quarterly Earnings on Tuesday
Nutanix  to Release Earnings on Monday
Nutanix to Release Earnings on Monday


© 2006-2019 Ticker Report